CTI BioPharma Corp. (CTIC)
Jun 26, 2023 - CTIC was delisted (reason: acquired by Sobi)
9.09
0.00 (0.00%)
Inactive · Last trade price on Jun 23, 2023

CTI BioPharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Ending
Current Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 2017 - 2013
Market Capitalization
1,1997632402379243
Upgrade
Market Cap Growth
18.67%218.03%0.98%159.24%115.34%-63.06%
Upgrade
Enterprise Value
1,25679222218967-10
Upgrade
PE Ratio
-16.23-8.20-2.45-4.53-2.29-1.45
Upgrade
PS Ratio
15.8214.14--27.391.62
Upgrade
PB Ratio
-21.84-43.3963.665.933.870.73
Upgrade
P/FCF Ratio
-6.73-9.39-2.82-5.62-3.29-1.07
Upgrade
P/OCF Ratio
-6.73-9.39-2.82-5.63-3.29-1.07
Upgrade
EV/Sales Ratio
16.5814.68--20.09-0.40
Upgrade
EV/EBITDA Ratio
-11.79-10.16-2.33-3.71-1.750.38
Upgrade
EV/EBIT Ratio
-11.32-9.92-2.32-3.67-1.720.37
Upgrade
EV/FCF Ratio
-7.42-9.75-2.61-4.49-2.420.26
Upgrade
Debt / Equity Ratio
-4.59-6.2112.580.110.390.24
Upgrade
Debt / EBITDA Ratio
-2.25-1.40-0.50-0.09-0.24-0.51
Upgrade
Debt / FCF Ratio
-1.41-1.34-0.56-0.11-0.33-0.35
Upgrade
Quick Ratio
1.201.170.983.081.823.50
Upgrade
Current Ratio
1.271.231.033.191.923.58
Upgrade
Asset Turnover
0.610.42000.050.26
Upgrade
Interest Coverage
-3.54-6.08-39.54-62.35-38.94-23.25
Upgrade
Return on Equity (ROE)
425.90%550.20%-298.90%-122.10%-109.10%-43.90%
Upgrade
Return on Assets (ROA)
-55.80%-72.20%-133.20%-73.40%-64.80%-29.60%
Upgrade
Return on Capital (ROIC)
-44.80%-83.00%1187.00%-1464.30%-227.70%-105.30%
Upgrade
Earnings Yield
-5.78%-12.19%-40.83%-22.09%-43.69%-69.11%
Upgrade
FCF Yield
-6.87%-10.65%-35.40%-17.78%-30.37%-93.69%
Upgrade
Buyback Yield / Dilution
-31.78%-27.27%-26.67%-22.71%-3.39%-53.86%
Upgrade
Total Shareholder Return
-31.78%-27.27%-26.67%-22.71%-3.39%-53.86%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).